Beset by challenges with its Alzheimer’s disease drug, Biogen pivots
May 03, 2022 at 12:47 PM EDT
The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |